Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
- Resource Type
- Article
- Authors
- Isa, Flonza; Forleo-Neto, Eduardo; Meyer, Jonathan; Zheng, Wenjun; Rasmussen, Scott; Armas, Danielle; Oshita, Masaru; Brinson, Cynthia; Folkerth, Steven; Faria, Lori; Heirman, Ingeborg; Sarkar, Neena; Musser, Bret J.; Bansal, Shikha; O'Brien, Meagan P.; Turner, Kenneth C.; Ganguly, Samit; Mahmood, Adnan; Dupljak, Ajla; Hooper, Andrea T.; Hamilton, Jennifer D.; Kim, Yunji; Kowal, Bari; Soo, Yuhwen; Geba, Gregory P.; Lipsich, Leah; Braunstein, Ned; Yancopoulos, George D.; Weinreich, David M.; Herman, Gary A.
- Source
- In International Journal of Infectious Diseases September 2022 122:585-592
- Subject
- Language
- ISSN
- 1201-9712